echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Tag pharma and baijiahui signed a cooperation agreement on clinical trial research and development of innovative drugs and medical devices

    Tag pharma and baijiahui signed a cooperation agreement on clinical trial research and development of innovative drugs and medical devices

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Taige Pharmaceutical (300347) announced in the evening of December 8 that the company and Nanjing baijiahui technology entrepreneurship community Co., Ltd (hereinafter referred to as "baijiahui") have reached a consensus on the clinical trial research and development cooperation of innovative drugs and medical devices and signed the strategic cooperation agreement, which is valid for 5 years According to reports, baijiahui is an open community of entrepreneurship, which is led and participated by Xiansheng Pharmaceutical Group, supported by government policies and coordinated by mature pharmaceutical enterprises, integrating R & D, entrepreneurship, investment and incubation The community is led by pharmaceutical companies, domestic and foreign scientific research institutions, global investment funds and other joint incubation and cultivation of drug innovation mode It introduces projects from global drug R & D innovation sources such as the United States, Europe, Canada, Israel, etc., to create a "Silicon Valley of life science" that gathers global wisdom According to the agreement, tag pharmaceutical provides the feasibility demonstration and clinical consulting services for the projects of innovative drugs and medical devices developed and to be introduced on baijiahui platform At the same time, the cooperation between the two parties includes but is not limited to the services that baijiahui entrusts tiger pharmaceutical to provide such as clinical supervision, data management and statistics, medical affairs, pharmacovigilance, quality control, personnel training, medical imaging, PK sample testing, central laboratory testing, experimental test samples and experimental goods logistics According to the needs of baijiahui's products and clinical development, tag pharmaceutical will also appoint specific personnel to form a directional service team to connect with baijiahui's relevant teams and personnel, and provide relevant services according to the contract signed by both parties on specific projects According to tiger Pharma, baijiahui is a new R & D platform for domestic innovative drugs, bringing together a large number of R & D enterprises of medical devices and drugs In five years, it is ready to invest in hundreds of life science innovation and entrepreneurship companies from around the world Through this strategic cooperation, the company will provide stable business sources for future development At the same time, this move will also establish a new cooperation mode for the company, improve the comprehensive service ability, and establish a broader cooperation network Tag Pharma: announcement date of signing strategic cooperation agreement with Nanjing baijiahui technology entrepreneurship community Co., Ltd and signing of baijiahui cro alliance 2014-12-08 securities code: 300347 securities abbreviation: tag Pharma announcement code (2014) No 097 Announcement of Hangzhou tiger Pharmaceutical Technology Co., Ltd on signing strategic cooperation agreement and cro alliance with Nanjing baijiahui technology entrepreneurship community Co., Ltd The company and all members of the board of directors shall guarantee the authenticity, accuracy and completeness of the contents of the announcement, and shall be jointly and severally liable for the false records, misleading statements or major omissions of the announcement I overview of the signing of the agreement: Hangzhou tiger Pharmaceutical Technology Co., Ltd (hereinafter referred to as "the company" or "Party B") and Nanjing baijiahui technology innovation community Co., Ltd (hereinafter referred to as "baijiahui" or "party a") are based on the principle of complementary advantages and sincere cooperation A strategic cooperation agreement was signed on the cooperation of clinical trial research and development of innovative drugs and medical devices Now the relevant information is announced as follows: 2 The partner introduces that baijiahui is an entrepreneurial open community led by Xiansheng Pharmaceutical Group, supported by government policies and coordinated by mature pharmaceutical enterprises, integrating R & D, entrepreneurship, investment and incubation The community is led by pharmaceutical enterprises, and jointly incubated and cultivated by domestic and foreign scientific research institutions, global investment funds and other pharmaceutical innovation models It introduces projects from global pharmaceutical R & D innovation sources such as the United States, Europe, Canada, Israel, etc to build a "life science Silicon Valley" that gathers global wisdom At the same time, baijiahui's cro alliance provides better services for innovation entrepreneurs in the field of life science III main contents of the agreement: 1 Main contents: (1) routine services Party B shall provide the feasibility certificate and clinical consulting services for the projects of innovative drugs and medical devices developed and to be introduced on Party A's platform (2) specific project services: Party A and Party B establish a comprehensive strategic cooperation relationship in the clinical research and development process of their drugs and medical devices Party B shall provide all-round technical services related to clinical research during the development of innovative drugs and medical devices on Party A's platform The cooperation between the two parties shall include but not limited to the clinical supervision, data management and statistics, medical affairs, pharmacovigilance, quality control, personnel training, medical imaging, PK sample testing and Center entrusted by Party A to Party B Laboratory testing, experimental test samples and experimental goods logistics and other services Party B will appoint specific personnel to form a targeted service team according to the needs of Party A's product and clinical development to connect with Party A's relevant teams and personnel, and provide relevant services according to the contract signed by both parties on specific projects As the main member of cro alliance, the company will improve the R & D efficiency of Party A's innovative drugs and medical devices, reduce the R & D cost, reduce the R & D risk, and make contribution to the early listing of its products 2 Term of cooperation: this strategic cooperation framework agreement is valid for 5 years Four, the impact of the implementation of the agreement on the company, baijiahui is a new R & D platform for domestic innovative drugs, bringing together a large number of R & D enterprises of medical devices and drugs, and is ready to invest in hundreds of life science innovation and entrepreneurship companies from all over the world within five years Through this strategic cooperation, we will provide stable business sources for the future development of the company At the same time, this move will also establish a new cooperation mode for the company, improve the comprehensive service ability, and establish a broader cooperation network V Risk Reminder: the signing of the cooperation agreement only stays at the level of strategic cooperation Before the company signs the specific project agreement, it will not have a significant impact on the normal production, operation and performance of the company, nor will it affect the business independence of the company The company will disclose the progress of the cooperation in a timely manner in strict accordance with the relevant regulations Please pay attention to the investment risks of investors Vi reference document 1 The strategic cooperation agreement between Nanjing baijiahui technology venture community Co., Ltd and Hangzhou Taige Pharmaceutical Technology Co., Ltd is hereby announced Board of directors of Hangzhou tiger Pharmaceutical Technology Co., Ltd December 8, 2014
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.